Compugen Ltd.

NasdaqCM:CGEN Rapport sur les actions

Capitalisation boursière : US$153.1m

Compugen Gestion

Gestion contrôle des critères 3/4

Compugen's CEO is Anat Cohen-Dayag, appointed in Jun 2009, has a tenure of 15.42 years. total yearly compensation is $1.46M, comprised of 32.7% salary and 67.3% bonuses, including company stock and options. directly owns 0.063% of the company’s shares, worth $95.97K. The average tenure of the management team and the board of directors is 5 years and 7.4 years respectively.

Informations clés

Anat Cohen-Dayag

Directeur général

US$1.5m

Rémunération totale

Pourcentage du salaire du PDG32.7%
Durée du mandat du directeur général15.4yrs
Propriété du PDG0.06%
Durée moyenne d'occupation des postes de direction5yrs
Durée moyenne du mandat des membres du conseil d'administration7.4yrs

Mises à jour récentes de la gestion

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28
Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08
Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

Compugen Q3 Earnings Preview

Nov 04

Analyse de la rémunération des PDG

Comment la rémunération de Anat Cohen-Dayag a-t-elle évolué par rapport aux bénéfices de Compugen?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$1mUS$479k

-US$19m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$479k

-US$34m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$1mUS$498k

-US$34m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$453k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$941kUS$395k

-US$27m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$854kUS$391k

-US$23m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$29m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$740kUS$392k

-US$37m

Rémunération vs marché: Anat's total compensation ($USD1.46M) is about average for companies of similar size in the US market ($USD1.48M).

Rémunération et revenus: Anat's compensation has increased whilst the company is unprofitable.

PDG

Anat Cohen-Dayag (57 yo)

15.4yrs

Titularisation

US$1,464,448

Compensation

Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Anat Cohen-Dayag
CEO, President & Director15.4yrsUS$1.46m0.063%
$ 96.0k
Eran Ophir
Chief Scientific Officer4.7yrsUS$540.64kpas de données
Zurit Levine
Senior Vice President of Technology Innovation6.8yrsUS$532.26kpas de données
Pierre Ferre
Vice President of Preclinical Development3.6yrsUS$570.40kpas de données
David Silberman
Chief Financial Officerless than a yearpas de donnéespas de données
Yvonne Naughton
Head of Investor Relations & Corporate Communicationsno datapas de donnéespas de données
Eran Dor
General Counsel & Corporate Secretary5.8yrspas de donnéespas de données
Dorit Amitay
Vice President of Human Resources17.8yrspas de donnéespas de données
Yaron Turpaz
Senior VP & Senior Advisor of Data and Informatics Solutions5yrspas de donnéespas de données
Rivka Schwartz
Vice President Research and Discoveryno datapas de donnéespas de données
Michelle Mahler
Chief Medical Officerless than a yearpas de donnéespas de données

5.0yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: CGEN's management team is seasoned and experienced (5 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Anat Cohen-Dayag
CEO, President & Director10.8yrsUS$1.46m0.063%
$ 96.0k
Nils Lonberg
Member of Scientific Advisory Board4.2yrspas de donnéespas de données
Sanford Zweifach
Independent Director6.4yrspas de donnéespas de données
Howard Soule
Member of Scientific Advisory Board11.3yrspas de donnéespas de données
Gilead Halevy
Independent Director6.4yrspas de donnéespas de données
Paul Sekhri
Independent Chairman of the Board7.1yrspas de donnéespas de données
Kinneret Livnat-Savitzky
Independent Director6.4yrspas de donnéespas de données
Andrew Pardoll
Chairman of Scientific Advisory Board10.8yrspas de donnéespas de données
Antoni Ribas
Member of Scientific Advisory Board11.3yrspas de donnéespas de données
Eran Perry
Independent Director5.3yrspas de donnéespas de données
Iain McInnes
Member of Scientific Advisory Board11.3yrspas de donnéespas de données
Miriam Merad
Member of Scientific Advisory Board7.7yrspas de donnéespas de données

7.4yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Conseil d'administration expérimenté: CGEN's board of directors are considered experienced (7.4 years average tenure).